Onconetix Inc Cash Flow Conversion Efficiency
Onconetix Inc cash flow conversion efficiency. Based on the latest financial reports, Onconetix Inc (ONCO) has a cash flow conversion efficiency ratio of -0.181x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.12 Million) by net assets ($11.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Onconetix Inc (2019–2025)
Cash flow conversion efficiency of Onconetix Inc from 2019 to 2025. This chart illustrates how Onconetix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ONCO share price today for real-time trading data and today's change.
Onconetix Inc Cash Flow Conversion Ratio Explained
Onconetix Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Onconetix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Onconetix Inc ranked by their cash flow conversion efficiency. Also see Onconetix Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mongolia Growth Group Ltd.
V:YAK-H
|
-0.015x |
|
AMNODE AB O.N.
F:Z9F0
|
N/A |
|
GlucoTrack Inc
NASDAQ:GCTK
|
2.077x |
|
IMMUTABLE HOLDINGS INC.
F:B8X0
|
-0.142x |
|
GROUNDED PEOPLE APPAREL
F:K1G
|
-0.024x |
|
LED iBond International AS
CO:LEDIBOND
|
-1.778x |
|
Asdion Bhd
KLSE:0068
|
0.009x |
|
SCANDIN.ENVIRO SYSTEMS AB
F:1HR
|
-0.151x |
Annual Cash Flow Conversion Efficiency for Onconetix Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Onconetix Inc from 2019 to 2025. Review Onconetix Inc leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $15.77 Million | $-9.68 Million | -0.614x | +43.79% |
| 2024-12-31 | $9.61 Million | $-10.50 Million | -1.092x | +88.71% |
| 2023-12-31 | $1.40 Million | $-13.58 Million | -9.670x | -2395.38% |
| 2022-12-31 | $22.39 Million | $-8.68 Million | -0.388x | +72.58% |
| 2021-12-31 | $1.45 Million | $-2.04 Million | -1.413x | -286.65% |
| 2020-12-31 | $4.73 Million | $-1.73 Million | -0.365x | -165.70% |
| 2019-12-31 | $6.00 Million | $-825.13K | -0.138x | -- |
About Onconetix Inc
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other … Read more